Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress
28 août 2017 08h30 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Aug. 28, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced posters on tucatinib in multiple tumor types will...
Cascadian Therapeutics Reports Second Quarter 2017 Financial Results
08 août 2017 16h01 HE
|
Cascadian Therapeutics, Inc.
First Patients Randomized in Western Europe and Australia in Ongoing Global HER2CLIMB Registrational Trial of Tucatinib Conference Call Scheduled for Today at 4:30 p.m. ET SEATTLE, Aug. 08, 2017 ...
Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017
01 août 2017 08h30 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter financial...
Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe
11 juil. 2017 08h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, July 11, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the outcome of discussions with the European...
Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases
08 juin 2017 08h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, June 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib, an investigational oral, small...
Cascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference
31 mai 2017 08h30 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, May 31, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Jefferies 2017...
Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET
09 mai 2017 07h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, May 09, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March...
Cascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017
01 mai 2017 08h56 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, May 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its financial results for the...
Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017
05 avr. 2017 08h00 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, April 05, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced data highlights from presentations of preclinical...
Cascadian Therapeutics Announces Changes to Board of Directors
13 mars 2017 16h01 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, March 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Robert W. Azelby has been appointed to the...